Characterization of mesenchymal stem cells (MSCs) and their use in the treatment of COVID-19

Title : Characterization of mesenchymal stem cells (MSCs) and their use in the treatment of COVID-19

Abstract:

OUTLINE

• Discuss the history and properties of MSCs
• Discuss rationale for use of uMSC in COVID-19
• Present institutional Protocol for use of uMSC in COVID-19  pneumonia
• Present local experience and outcome of patients treated with  uMSC with COVID-19

Keywords: MSCs, uMSC, COVID-19, pneumonia.

Biography:

Vasiliki E. Kalodimou is the Collaborative partner for training and research for Regenerative Medicine Program at the Institute of Personalized Molecular Medicine at the Medical City Hospital, Philippines, the Board/Committee on Research Ethics at the National Hellenic Research Foundation, the Vice-Chair of the UEL Alumni Advisory Board,  previously was the Director at the Flow Cytometry-Research and Regenerative Medicine Department of IASO in Greece, as well as the CBB & Processing Facility Director at MedStem-Cryobanks. In addition to collaboration with state universities and pharmaceutical companies on research projects (17), frequently publishes (46 & 9 books) her findings. She has 2 patents.